Compositions for treatment of wet age-related macular degeneration
Inventors
Wilson, James M. • YOO, Stephen • Van Everen, Sherri • Bennett, Jean • Maguire, Albert M. • Aleman, Tomas Santiago • Marshall, Tristan James • Tretiakova, Anna
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
A liquid suspension product comprising a recombinant adeno-associated virus (rAAV) having an AAV8 capsid which is suitable for intra-retinal injection is provided herein. Also provided herein are liquid suspensions containing these rAAV8.aVEGF and methods of using same for treatment of wet AMD and other ocular conditions.
Core Innovation
The invention describes ocular delivery of a recombinant AAV8 vector encoding an anti-human vascular endothelial growth factor antigen-binding fragment comprising heavy and light immunoglobulin chains. Regulatory elements direct expression of the antigen-binding fragment in the eye to inhibit human vascular endothelial growth factor and treat retinal diseases, including neovascular age-related macular degeneration. Single-dose vector administration directs retinal transduction and achieves antigen-binding fragment expression across retinal regions and ocular fluids.
Reported preclinical evaluations demonstrate sustained transgene expression alongside structural and functional ocular findings, including dose-associated retinal changes and electroretinography observations at higher evaluated doses. In these evaluations, antigen-binding fragment is not detected above background in blood, vector shedding remains transient, and sustained immune responses are absent. The technology provides continuous local VEGF inhibition over designated periods with fewer repeat ocular injections.
Claims Coverage
The claims identify four independent claims covering four inventive features directed to ocular delivery of an AAV8 vector encoding an anti-hVEGF Fab for treating retinal diseases and inhibiting VEGF in the eye.
Subretinal administration for neovascular age-related macular degeneration
The claim covers subretinal administration of a liquid or aqueous suspension containing an AAV8 vector encoding anti-hVEGF Fab heavy and light chains with expression-directing regulatory elements to a human patient with neovascular age-related macular degeneration.
Single-dose delivery of an anti-hVEGF Fab to the eye
The claim covers delivering a single dose of an aqueous suspension containing an AAV8 vector encoding anti-hVEGF Fab heavy and light chains into a human patient's eye, wherein regulatory elements comprise a chicken beta-actin promoter.
Single-dose treatment of neovascular age-related macular degeneration
The claim covers treating neovascular age-related macular degeneration for at least a 12-month period in the absence of adverse drug-related ocular events using a single per-eye dose of an AAV8 vector encoding an anti-hVEGF Fab with a chicken beta-actin promoter and a rabbit beta-globin polyadenylation signal.
Ocular inhibition of human vascular endothelial growth factor
The claim covers administering a single ocular dose of an AAV8 vector comprising a CMV IE enhancer, a chicken beta-actin promoter and intron, and a rabbit beta-globin polyadenylation signal to inhibit hVEGF, maintaining effective anti-hVEGF Fab expression at six months and safety during 12 months without additional dosing to treat an associated retinal disease.
Together, the four inventive features define AAV8-mediated ocular expression of an anti-hVEGF Fab, encompassing subretinal administration, single-dose delivery, extended treatment duration without adverse ocular events, and sustained VEGF inhibition.
Stated Advantages
The proposed approach provides continuous local VEGF inhibition.
The proposed approach may result in fewer repeat ocular injections.
The vector achieves treatment of neovascular age-related macular degeneration for at least a 12-month period in the absence of adverse drug-related ocular events with a single dose per eye.
A single dose maintains effective anti-hVEGF Fab expression in the eye at six months and is safe during 12 months without additional dosing.
A single dose is effective in treating a retinal disease associated with human vascular endothelial growth factor.
Documented Applications
Treatment of neovascular age-related macular degeneration.
Treatment of diabetic retinopathy.
Treatment of diabetic macular edema.
Inhibition of human vascular endothelial growth factor in the eye for treatment of a retinal disease associated with human vascular endothelial growth factor.
Interested in licensing this patent?